首页 › 基金 › BOONE CAPITAL MANAGEMENT LLC › CGEM
BOONE CAPITAL MANAGEMENT LLC 对 CGEM 的持仓历史
CULLINAN THERAPEUTICS INC · 医疗保健
BOONE CAPITAL MANAGEMENT LLC 在 Q3 2026 的 13F 申报中披露持有 CGEM(CULLINAN THERAPEUTICS INC)690,814 股,市值约 US$10.6M,约占其申报组合的 2.81%,在其申报持仓中市值排名第 14 位。 BOONE CAPITAL MANAGEMENT LLC 最近 2 个申报季度中有 2 个季度披露了 CGEM 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
BOONE CAPITAL MANAGEMENT LLC 对 CGEM 的持仓演变
BOONE CAPITAL MANAGEMENT LLC 于 Q2 2026 首次披露 CGEM 持仓:704,442 股(约 US$12.8M)。 在 2 次申报中,BOONE CAPITAL MANAGEMENT LLC 0 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 690,814 股、市值约 US$10.6M,环比减持 -13,628 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 704.44K | $12.83M | 新进 |
| Q3 2026 | 690.81K | $10.60M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CGEM 与 13F 数据
CGEM(CULLINAN THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 31 只申报持有 CGEM,申报仓位最大的包括:MPM BioImpact LLC (US$149.2M), Lynx1 Capital Management LP (US$137.6M), BVF INC/IL (US$88.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CGEM 的基金
- MPM BioImpact LLC 9.72M 股 · $149.22M · Q3 2026
- Lynx1 Capital Management LP 8.96M 股 · $137.59M · Q3 2026
- BVF INC/IL 5.75M 股 · $88.27M · Q3 2026
- Kynam Capital Management, LP 3.11M 股 · $47.80M · Q3 2026
- RTW INVESTMENTS, LP 2.36M 股 · $36.29M · Q3 2026
- Siren, L.L.C. 1.79M 股 · $27.53M · Q3 2026
- Blue Owl Capital Holdings LP 1.40M 股 · $21.49M · Q3 2026
- Venrock Adviser, LLC 1.38M 股 · $21.18M · Q3 2026
- Elmind Capital, LP 962.79K 股 · $14.78M · Q3 2026
- Affinity Asset Advisors, LLC 875.76K 股 · $13.44M · Q3 2026
- TWIN FOCUS CAPITAL PARTNERS, LLC 595.49K 股 · $9.14M · Q3 2026
- Boxer Capital Management, LLC 450.00K 股 · $6.91M · Q3 2026
更多关于 BOONE CAPITAL MANAGEMENT LLC
常见问题
How long has BOONE CAPITAL MANAGEMENT LLC held CGEM?
BOONE CAPITAL MANAGEMENT LLC has disclosed CGEM holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is BOONE CAPITAL MANAGEMENT LLC's current position in CGEM?
As of Q3 2026, BOONE CAPITAL MANAGEMENT LLC holds 690.81K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $10.60M, representing 2.81% of its reported portfolio and ranking #14.
Has BOONE CAPITAL MANAGEMENT LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), BOONE CAPITAL MANAGEMENT LLC reduced its position in CGEM.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.